Literature DB >> 18167338

GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

Tiebang Kang1, Yongkun Wei, Yuchi Honaker, Hiroshi Yamaguchi, Ettore Appella, Mien-Chie Hung, Helen Piwnica-Worms.   

Abstract

The Cdc25A phosphatase positively regulates cell-cycle transitions, is degraded by the proteosome throughout interphase and in response to stress, and is overproduced in human cancers. The kinases targeting Cdc25A for proteolysis during early cell-cycle phases have not been identified, and mechanistic insight into the cause of Cdc25A overproduction in human cancers is lacking. Here, we demonstrate that glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Cdc25A to promote its proteolysis in early cell-cycle phases. Phosphorylation by GSK-3beta requires priming of Cdc25A, and this can be catalyzed by polo-like kinase 3 (Plk-3). Importantly, a strong correlation between Cdc25A overproduction and GSK-3beta inactivation was observed in human tumor tissues, indicating that GSK-3beta inactivation may account for Cdc25A overproduction in a subset of human tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18167338      PMCID: PMC2276649          DOI: 10.1016/j.ccr.2007.12.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  63 in total

1.  Rapid destruction of human Cdc25A in response to DNA damage.

Authors:  N Mailand; J Falck; C Lukas; R G Syljuâsen; M Welcker; J Bartek; J Lukas
Journal:  Science       Date:  2000-05-26       Impact factor: 47.728

2.  Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation.

Authors:  R Bernardi; D A Liebermann; B Hoffman
Journal:  Oncogene       Date:  2000-05-11       Impact factor: 9.867

3.  Role of the Cdc25A phosphatase in human breast cancer.

Authors:  M G Cangi; B Cukor; P Soung; S Signoretti; G Moreira; M Ranashinge; B Cady; M Pagano; M Loda
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.

Authors:  P R Graves; L Yu; J K Schwarz; J Gales; E A Sausville; P M O'Connor; H Piwnica-Worms
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.

Authors:  M Broggini; G Buraggi; A Brenna; L Riva; A M Codegoni; V Torri; A A Lissoni; C Mangioni; M D'Incalci
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

Review 6.  Pathways governing G1/S transition and their response to DNA damage.

Authors:  J Bartek; J Lukas
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

7.  The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

Authors:  E C Busby; D F Leistritz; R T Abraham; L M Karnitz; J N Sarkaria
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

8.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

Authors:  Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

9.  cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.

Authors:  S Hernández; L Hernández; S Bea; M Pinyol; I Nayach; B Bellosillo; A Nadal; A Ferrer; P L Fernández; E Montserrat; A Cardesa; E Campo
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

10.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Authors:  M P Coghlan; A A Culbert; D A Cross; S L Corcoran; J W Yates; N J Pearce; O L Rausch; G J Murphy; P S Carter; L Roxbee Cox; D Mills; M J Brown; D Haigh; R W Ward; D G Smith; K J Murray; A D Reith; J C Holder
Journal:  Chem Biol       Date:  2000-10
View more
  92 in total

1.  A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.

Authors:  Yongsheng Wu; Xiaoling Feng; Yucui Jin; Zhaojia Wu; William Hankey; Carolyn Paisie; Lei Li; Fengjuan Liu; Sanford H Barsky; Weiwei Zhang; Ramesh Ganju; Xianghong Zou
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

2.  DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.

Authors:  Naoe Taira; Rei Mimoto; Morito Kurata; Tomoko Yamaguchi; Masanobu Kitagawa; Yoshio Miki; Kiyotsugu Yoshida
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 3.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

4.  Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.

Authors:  Mar Mora-Santos; M Cristina Limón-Mortés; Servando Giráldez; Joaquín Herrero-Ruiz; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 5.  Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Nat Rev Mol Cell Biol       Date:  2013-09       Impact factor: 94.444

6.  PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Authors:  Edita Aksamitiene; Boris N Kholodenko; Walter Kolch; Jan B Hoek; Anatoly Kiyatkin
Journal:  Cell Signal       Date:  2010-05-12       Impact factor: 4.315

Review 7.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Curr Opin Cell Biol       Date:  2009-02-21       Impact factor: 8.382

Review 8.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

Review 9.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Downregulation of LncRNAH19 and MiR-675 promotes migration and invasion of human hepatocellular carcinoma cells through AKT/GSK-3β/Cdc25A signaling pathway.

Authors:  Jun Lv; Ling Ma; Xi-Lin Chen; Xiao-Hui Huang; Qian Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.